Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 45 years~* Established diagnosis of SCD-SS or SCD-SB0-thal~* At medical baseline, with no evidence of worsening of disease over the last 3 months~* Available and agree to return for follow-up visits for the full duration of the study~* Able to cooperate with study procedures~* Documented and observed written informed consent~Exclusion Criteria:~* Vaso-occlusive crisis~* Recent major surgery, hospitalization, infection, significant bleeding, cerebrovascular accident or seizure, or transfusion~* Currently receiving, or has received within the previous 4 weeks, any other investigational agent~* Pregnant or lactating female; or female of childbearing age unable or unwilling to comply with birth control or abstinence during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- GMI-1070 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).